Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Global Market Report 2025
상품코드:1760540
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 규모는 향후 몇 년 동안 16.6%의 연평균 복합 성장률(CAGR)로 2029년까지 289억 1,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 효과적인 체중 감량 솔루션에 대한 수요 증가, 비당뇨병 적응증 확대, R&D 투자 증가, 맞춤형 의료 채택 증가, 소비자 직접 판매를 통한 인지도 상승 등에 기인할 것으로 보입니다. 예측 기간 동안 주요 동향으로는 경구용 글루카곤 유사 펩타이드(GLP)-1 제제 개발, 서방형 약물전달의 발전, 모니터링용 디지털 헬스 툴의 통합, 신약 개발 및 개발에 인공지능 활용, 유효성 향상을 위한 펩타이드 엔지니어링의 혁신 등이 있습니다.
비만 유병률의 증가는 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장의 성장을 촉진할 것으로 예상됩니다. 비만은 건강에 위험을 초래하는 과도한 체지방 축적을 특징으로 하는 질환으로, 적절한 영양이 부족한 패스트푸드와 당분이 많은 음료의 섭취 증가 등 건강에 해로운 식습관으로 인해 점점 더 흔해지고 있습니다. 비만과 그에 따른 합병증으로 고통받는 사람들의 수가 계속 증가함에 따라 효과적인 치료 옵션에 대한 수요도 증가하고 있습니다. 이에 따라 체중 감소를 돕고 신진대사 건강을 개선하는 것으로 입증된 글루카곤 유사 펩타이드(GLP)-1 작용제(GLP-1)를 활용한 체중 감량 치료제가 각광받고 있습니다. 예를 들어, 2024년 3월 세계보건기구(WHO)는 2022년에는 전 세계 인구 8명 중 1명이 비만을 앓고 있으며, 25억 명의 과체중 성인 중 약 8억 9,000만 명이 비만으로 분류된다고 보고했습니다. 또한 전 세계 성인 인구의 43%가 과체중이며, 16%는 비만인 것으로 나타났습니다. 이처럼 비만 유병률의 증가는 GLP-1 작용제 체중감량제 시장의 성장을 촉진하고 있습니다.
GLP-1 작용제 체중감량제 시장의 주요 기업들은 비만 치료의 효과를 높이고 환자 결과를 개선하는 혁신적인 치료법을 도입하고 있습니다. 이 치료제는 GLP-1 호르몬을 모방하여 식욕을 조절하고 포만감을 증가시키며 체중 감소를 촉진합니다. 대사 기능을 개선함으로써 장기적인 체중 관리와 비만 억제를 지원합니다. 예를 들어, 2023년 11월 미국 제약회사 일라이 릴리(Eli Lilly and Company)는 미국 식품의약국(FDA)으로부터 비만 및 과체중 성인, 특히 제2형 당뇨병 및 수면무호흡증과 같은 관련 질환을 앓고 있는 성인의 만성적인 체중 조절을 위한 약물인 제프바운드(ZebraBound)를 승인받았습니다. 이 약은 GIP와 GLP-1 두 호르몬 수용체를 활성화시켜 식욕을 억제하고 대사 기능을 개선합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 : 성장률 분석
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 실적 : 규모와 성장, 2019-2024년
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 전체 시장(TAM)
제6장 시장 세분화
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 : 약제별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Semaglutide
Liraglutide
Tirzepatide
기타 약제
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
비경구
경구
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
기타 약국
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장, Semaglutide 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Ozempic
Wegovy
Rybelsus
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장, Liraglutide 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Saxenda
Victoza
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장, Tirzepatide 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Mounjaro
Zepbound
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장, 기타 약제 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Exenatide
Dulaglutide
Albiglutide
Efpeglenatide
제7장 지역별·국가별 분석
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 : 경쟁 구도
글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Novo Nordisk A/S
Teva Pharmaceutical Industries Ltd
Boehringer Ingelheim
Jiangsu Hengrui Medicine Co. Ltd
BioAge Labs
Hanmi Pharmaceutical
Innovent Biologics Inc.
Viking Therapeutics Inc.
Structure Therapeutics Inc.
Zealand Pharma A/S
Regor Therapeutics Inc.
I-Mab Biopharma(Shanghai) Co. Ltd.
Altimmune Inc.
TheracosBio LLC.
Oramed Pharmaceuticals
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 2029년 : 새로운 기회를 제공하는 국가
글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 2029년 : 새로운 기회를 제공하는 부문
글루카곤 유사 펩타이드(GLP)-1 작용제 체중감량제 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Glucagon-like peptide (GLP)-1 agonists are medications that mimic the action of the GLP-1 hormone, helping to regulate blood sugar levels and curb appetite. They promote insulin release, slow gastric emptying, and enhance feelings of satiety. Originally developed for managing type 2 diabetes, these drugs are now widely used for weight management in overweight and obese individuals.
The key drugs in the GLP-1 agonists weight loss market include semaglutide, liraglutide, tirzepatide, and other medications. Semaglutide, branded as Wegovy, is an injectable prescription drug designed to support weight loss in adults with obesity or overweight conditions coupled with weight-related health problems. These medications are available in both parenteral and oral forms and are distributed through hospital pharmacies, retail pharmacies, and other outlets.
The glucagon-like peptide (GLP)-1 agonists weight loss drugs market research report is one of a series of new reports from The Business Research Company that provides glucagon-like peptide (GLP)-1 agonists weight loss drugs market statistics, including glucagon-like peptide (GLP)-1 agonists weight loss drugs industry global market size, regional shares, competitors with a glucagon-like peptide (GLP)-1 agonists weight loss drugs market share, detailed glucagon-like peptide (GLP)-1 agonists weight loss drugs market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide (GLP)-1 agonists weight loss drugs industry. The glucagon-like peptide (GLP)-1 agonists weight loss drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The glucagon-like peptide (GLP) -1 agonists weight loss drugs market size has grown rapidly in recent years. It will grow from$13.38 billion in 2024 to $15.63 billion in 2025 at a compound annual growth rate (CAGR) of 16.9%. The growth during the historic period can be attributed to the rising prevalence of obesity, the increasing incidence of type 2 diabetes, greater awareness of obesity-related health risks, higher healthcare spending, a growing focus on chronic disease management, and improved access to healthcare.
The glucagon-like peptide (GLP) -1 agonists weight loss drugs market size is expected to see rapid growth in the next few years. It will grow to$28.91 billion in 2029 at a compound annual growth rate (CAGR) of 16.6%. The growth during the forecast period can be attributed to the growing demand for effective weight loss solutions, the expansion of drug indications beyond diabetes, increased investments in research and development, the rising adoption of personalized medicine, and heightened awareness through direct-to-consumer marketing. Key trends in the forecast period include the development of oral glucagon-like peptide (GLP)-1 formulations, advancements in sustained-release drug delivery, integration of digital health tools for monitoring, the use of artificial intelligence in drug discovery and development, and innovations in peptide engineering to enhance efficacy.
The growing prevalence of obesity is expected to fuel the expansion of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market. Obesity, a medical condition marked by excessive body fat accumulation that poses health risks, is becoming more common due to unhealthy eating habits, such as the increased consumption of fast food and sugary drinks, which lack proper nutrition. As the number of individuals affected by obesity and its associated complications continues to grow, the demand for effective treatment options is also rising. This is driving the adoption of glucagon-like peptide (GLP)-1 agonist weight loss drugs, which have proven efficacy in supporting weight loss and improving metabolic health. For example, in March 2024, the World Health Organization reported that in 2022, one in eight people globally were living with obesity. Among the 2.5 billion overweight adults, approximately 890 million were classified as obese. Furthermore, 43% of the global adult population was overweight, and 16% were considered obese. Thus, the increasing prevalence of obesity is propelling the growth of the GLP-1 agonist weight loss drugs market.
Leading companies in the GLP-1 agonist weight loss drugs market are introducing innovative therapies to improve the efficacy of obesity treatment and enhance patient outcomes. These therapies mimic the GLP-1 hormone to regulate appetite, increase satiety, and promote weight loss. By improving metabolic function, these drugs support long-term weight management and obesity control. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical firm, received approval from the US Food and Drug Administration for Zepbound, a medication designed for chronic weight management in adults with obesity or overweight, especially those with related health conditions such as type 2 diabetes or sleep apnea. The drug works by activating both GIP and GLP-1 hormone receptors to suppress appetite and improve metabolic function.
In December 2023, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics for $2.7 billion. This acquisition enables Roche to access Carmot's pipeline of incretin-based therapies for obesity and diabetes, including dual GLP-1/GIP receptor agonists CT-388 and CT-868, as well as GLP-1 receptor agonist CT-996. Carmot Therapeutics, a US-based biotechnology company, specializes in developing disease-modifying therapies for metabolic diseases such as obesity and diabetes.
Major players in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc, Amgen Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Jiangsu Hengrui Medicine Co. Ltd, BioAge Labs, Hanmi Pharmaceutical, Innovent Biologics Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., Zealand Pharma A/S, Regor Therapeutics Inc., I-Mab Biopharma (Shanghai) Co. Ltd., Altimmune Inc., TheracosBio LLC., and Oramed Pharmaceuticals.
North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in glucagon-like peptide (GLP)-1 agonists weight loss drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The glucagon-like peptide (GLP)-1 agonists weight loss drugs market consists of sales of products such as dulaglutide (trulicity), exenatide (byetta, bydureon), and lixisenatide (adlyxin). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on glucagon-like peptide (glp)-1 agonists weight loss drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for glucagon-like peptide (glp)-1 agonists weight loss drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glucagon-like peptide (glp)-1 agonists weight loss drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drugs: Semaglutide; Liraglutide; Tirzepatide; Other Drugs
2) By Route of Administration: Parenteral; Oral
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies
Subsegments:
1) By Semaglutide: Ozempic; Wegovy; Rybelsus
2) By Liraglutide: Saxenda; Victoza
3) By Tirzepatide: Mounjaro; Zepbound
4) By Other Drugs: Exenatide; Dulaglutide; Albiglutide; Efpeglenatide
Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc; Amgen Inc.; Eli Lilly and Company
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Characteristics
3. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Trends And Strategies
4. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth Rate Analysis
5.4. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Total Addressable Market (TAM)
6. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segmentation
6.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Semaglutide
Liraglutide
Tirzepatide
Other Drugs
6.2. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Parenteral
Oral
6.3. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Other Pharmacies
6.4. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Semaglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ozempic
Wegovy
Rybelsus
6.5. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Saxenda
Victoza
6.6. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Tirzepatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mounjaro
Zepbound
6.7. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Exenatide
Dulaglutide
Albiglutide
Efpeglenatide
7. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Regional And Country Analysis
7.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
9.1. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
9.2. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
10.1. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
11.1. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
11.2. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
12.1. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
13.1. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
14.1. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
14.2. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
15.1. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
15.2. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
16.1. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
17.1. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
18.1. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
19.1. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
20.1. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
21.1. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
21.2. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
22.1. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
23.1. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
23.2. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
24.1. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
24.2. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
25.2. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
26.1. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
26.2. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
27.1. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
28.1. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
28.2. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market
29.1. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
29.2. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Competitive Landscape And Company Profiles
